Characteristics of late acute GVHD at onset
| Characteristic, n (%) . | BMT . | PBSCT . | ||||
|---|---|---|---|---|---|---|
| Japanese (n = 53) . | White (n = 12) . | P . | Japanese (n = 25) . | White (n = 96) . | P . | |
| Months from transplantation to late acute GVHD, median (IQR) | 5.6 (4.4-8.3) | 5.4 (4.1-6.5) | .51 | 5.8 (4.3-6.9) | 4.7 (3.5-6.5) | .06 |
| Type | .34 | <.001 | ||||
| Late onset | 15 (26) | 2 (17) | 13 (52) | 12 (13) | ||
| Recurrent | 31 (58) | 10 (83) | 9 (36) | 81 (84) | ||
| Persistent | 7 (13) | 0 (0) | 3 (12) | 3 (3) | ||
| Sites involved | ||||||
| Skin | 40 (75) | 6 (50) | .16 | 13 (52) | 50 (52) | 1.0 |
| Liver (per the 1994 consensus) | 4 (8) | 0 (0) | 1.0 | 3 (12) | 8 (8) | .70 |
| Liver (per the 2005 NIH liver score) | 42 (79) | 1 (8) | <.001 | 23 (92) | 31 (33) | <.001 |
| Gastrointestinal tract | 6 (11) | 7 (58) | .001 | 5 (20) | 65 (68) | <.001 |
| Grade of late acute GVHD | .024 | .001 | ||||
| Grade II or lower | 47 (89) | 7 (58) | 20 (80) | 39 (41) | ||
| Grade III or higher | 6 (11) | 5 (42) | 5 (20) | 57 (59) | ||
| No. of involved sites | .025 | .44 | ||||
| 1 | 21 (40) | 10 (83) | 11 (44) | 54 (56) | ||
| 2 | 29 (54) | 2 (17) | 12 (48) | 33 (34) | ||
| 3 | 3 (6) | 0 (0) | 2 (8) | 9 (9) | ||
| Prior IIb-IV classic acute GVHD | 29 (55) | 5 (42) | .53 | 9 (36) | 45 (47) | .37 |
| Karnofsky Performance Status | .028 | .34 | ||||
| 80%-100% | 42 (79) | 6 (50) | 16 (64) | 46 (48) | ||
| <80% | 11 (21) | 5 (42) | 9 (36) | 47 (49) | ||
| Unknown | 0 (0) | 1 (8) | 0 (0) | 3 (3) | ||
| Dose of prednisone, mg/kg | .59 | .72 | ||||
| None | 44 (83) | 9 (75) | 21 (84) | 74 (77) | ||
| >0 but <0.5 | 7 (13) | 3 (25) | 4 (16) | 14 (15) | ||
| 0.5-1.0 | 2 (4) | 0 (0) | 0 (0) | 6 (6) | ||
| >1.0 | 0 (0) | 0 (0) | 0 (0) | 2 (2) | ||
| Platelet count <100 × 109/L | 22 (42) | 5 (42) | 1.0 | 5 (20) | 20 (21) | 1.0 |
| Serum bilirubin level >2 mg/dL | 4 (8) | 0 (0) | 1.0 | 3 (12) | 8 (8) | .70 |
| Characteristic, n (%) . | BMT . | PBSCT . | ||||
|---|---|---|---|---|---|---|
| Japanese (n = 53) . | White (n = 12) . | P . | Japanese (n = 25) . | White (n = 96) . | P . | |
| Months from transplantation to late acute GVHD, median (IQR) | 5.6 (4.4-8.3) | 5.4 (4.1-6.5) | .51 | 5.8 (4.3-6.9) | 4.7 (3.5-6.5) | .06 |
| Type | .34 | <.001 | ||||
| Late onset | 15 (26) | 2 (17) | 13 (52) | 12 (13) | ||
| Recurrent | 31 (58) | 10 (83) | 9 (36) | 81 (84) | ||
| Persistent | 7 (13) | 0 (0) | 3 (12) | 3 (3) | ||
| Sites involved | ||||||
| Skin | 40 (75) | 6 (50) | .16 | 13 (52) | 50 (52) | 1.0 |
| Liver (per the 1994 consensus) | 4 (8) | 0 (0) | 1.0 | 3 (12) | 8 (8) | .70 |
| Liver (per the 2005 NIH liver score) | 42 (79) | 1 (8) | <.001 | 23 (92) | 31 (33) | <.001 |
| Gastrointestinal tract | 6 (11) | 7 (58) | .001 | 5 (20) | 65 (68) | <.001 |
| Grade of late acute GVHD | .024 | .001 | ||||
| Grade II or lower | 47 (89) | 7 (58) | 20 (80) | 39 (41) | ||
| Grade III or higher | 6 (11) | 5 (42) | 5 (20) | 57 (59) | ||
| No. of involved sites | .025 | .44 | ||||
| 1 | 21 (40) | 10 (83) | 11 (44) | 54 (56) | ||
| 2 | 29 (54) | 2 (17) | 12 (48) | 33 (34) | ||
| 3 | 3 (6) | 0 (0) | 2 (8) | 9 (9) | ||
| Prior IIb-IV classic acute GVHD | 29 (55) | 5 (42) | .53 | 9 (36) | 45 (47) | .37 |
| Karnofsky Performance Status | .028 | .34 | ||||
| 80%-100% | 42 (79) | 6 (50) | 16 (64) | 46 (48) | ||
| <80% | 11 (21) | 5 (42) | 9 (36) | 47 (49) | ||
| Unknown | 0 (0) | 1 (8) | 0 (0) | 3 (3) | ||
| Dose of prednisone, mg/kg | .59 | .72 | ||||
| None | 44 (83) | 9 (75) | 21 (84) | 74 (77) | ||
| >0 but <0.5 | 7 (13) | 3 (25) | 4 (16) | 14 (15) | ||
| 0.5-1.0 | 2 (4) | 0 (0) | 0 (0) | 6 (6) | ||
| >1.0 | 0 (0) | 0 (0) | 0 (0) | 2 (2) | ||
| Platelet count <100 × 109/L | 22 (42) | 5 (42) | 1.0 | 5 (20) | 20 (21) | 1.0 |
| Serum bilirubin level >2 mg/dL | 4 (8) | 0 (0) | 1.0 | 3 (12) | 8 (8) | .70 |
IQR, interquartile range.